eli lilly retatrutide clinical trials Retatrutide, Lilly's next generation of weight loss injections, showed dramatic results in trials, with patients losing an average of up to 71.2 pounds, or 28.7% of their body weight. Eli Eli Lilly says next-generation weight

Conclusion Clinical trial data from large, controlled studies demonstrate the efficacy and safety of GLP-1 agonists in terms of A1C reduction, beneficial effects on body weight, and a low risk for hypoglycemic events when used as monotherapy

2025;169(2):e16242

Obesity and Weight Loss Research : GLP-1 receptor activation leads to appetite suppression and increased satiety , making it a powerful tool for studying obesity and the development of weight loss therapies

The good news is that many users of branded GLP-1s qualify for partial or full insurance coverage, especially if they have diabetes or a BMI over 30

[DOI] [PubMed] [Google Scholar] 131.Jones K.L., Rigda R.S., Buttfield M.D.M., et al

Retatrutide arrives as a lyophilized powder and requires reconstitution with bacteriostatic sterile water